Guided Solutions’ Post

Fluid Biomed Inc. completed a $27m #SeriesA equity financing round to advance the development of its innovative ReSolv stent for treating brain aneurysms. Led by Amplitude Ventures, the oversubscribed #fundinground also included participation from new investors, including IAG Capital Partners and LifeArc Ventures and returning investors ShangBay Capital and METIS Innovative. CEO Dr John Wong shared:  “Our exclusive technology has attracted the attention of international investors of the highest calibre with the depth and breadth of expertise to accelerate company evolution and make its medical devices available sooner to physicians and patients.” 💬 Read more: https://lnkd.in/dn82adJe #MedicalDevice #MedTech #MedicalEquipment #HealthTech #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

🥼 SpectraWAVE, Inc. brought in a $50 million Series B financing round to advance the commercial expansion and product addition efforts, related to its FDA 510(k)-cleared HyperVue imaging system. The device is designed to improve the treatment and outcomes for patients with coronary artery disease. 👏 “This is an important step in our journey to enhance the clinical decision-making for these patients and establish an anchor point for future innovation in the cath lab,” said Eman Namati, CEO. 🔗 Read more: https://lnkd.in/dfbwWSq7 ❗ Subscribe to our weekly newsletter to receive the latest #MedTech news and insights: https://lnkd.in/d6tmiv-u #MedicalDevices #MedicalDevice #MedicalEquipment #HealthTech #GuidedSolutions #ExecutiveSearch

The future of medical procedures is here! 🏥💉 Ultrasound-guided puncture needles are changing the game in minimally invasive techniques. A new market report reveals exciting growth prospects for this technology in North America. Key takeaways: • Market expected to grow at 4.5% CAGR from 2023-2030 • Rising demand for precise, less invasive procedures • Major players include Medtronic, Becton Dickinson, and Boston Scientific Interested in learning more about the future of #POCUS? Check out the full report!

The #BioresorbableVascularScaffold (BVS) market has seen significant growth in recent months, driven by advancements in patient care and long-term vascular health: Abbott (Abbott) has continued to lead the market with its latest investments in Absorb Bioresorbable Vascular Scaffolds, enhancing clinical trials aimed at improving patient outcomes, with a reported $100M investment in R&D in 2024. Kyoto Medical (Kyoto Medical Planning Co., Ltd.) has expanded its market share in Asia, investing $45M in the development of next-gen bioresorbable scaffolds aimed at better long-term vessel support. Biotronik (BIOTRONIK) continues to push the boundaries with its Magmaris Bioresorbable Scaffold, having secured $80M in new funding to accelerate production and innovation. Elixir Medical (Elixir Medical Corporation) recently announced an additional $50M investment to support the commercial launch of its DynamX Bioresorbable Scaffold, promising to revolutionize patient outcomes globally. Read Report @ https://lnkd.in/gYwcP4n7 #HealthcareInnovation #CardiovascularResearch #MedicalDevices #BioresorbableScaffolds #VascularHealth #ClinicalTrials #MedicalResearch #HealthcareTrends #HeartHealth #MedTech #BiotechInvestments #GlobalHealth #DigitalHealth #HealthcareTechnology #RegenerativeMedicine #HealthCare #FutureOfHealthcare #MedicalBreakthroughs #HealthTech #PatientCare #PharmaceuticalResearch #BioresorbableScaffolds #CardiovascularHealth #MedicalDevices #VascularSurgery #InterventionalCardiology #HealthcareInnovation #TissueEngineering #Bioengineering #MedicalResearch #StentTechnology #CardiacCare #HealthTech #Biomaterials #Angioplasty #VascularInterventions #ClinicalTrials #HealthcareTrends #RegenerativeMedicine #SurgicalInnovation #PatientCare

Revolutionizing Treatment: Exploring the 𝐍𝐞𝐮𝐫𝐨𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐢𝐨𝐧 Market 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/dy9AMhQp The global 𝐍𝐞𝐮𝐫𝐨𝐦𝐨𝐝𝐮𝐥𝐚𝐭𝐢𝐨𝐧 market in terms of revenue was estimated to be worth $6.2 Billion in 2023 and is poised to reach $11.0 Billion by 2028, growing at a CAGR of 12.0% from 2023 to 2028. 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: - Medtronic Plc (Ireland), - Boston Scientific (US), - Abbott (US) - Nevro - LivaNova PLC - Theranica - Cala Health - electroCore, Inc. - Neuros Medical, Inc. - Saluda Medical - Neuronetics, Inc. - Soterix Medical - Synapse Biomedical - Cognito Therapeutics, Inc. - INBRAIN Neuroelectronics - NeuroSigma - Xana, Smart Neurostimulation - Mainstay Medical - Inspire Medical Systems - Inspire Sleep - SPR Therapeutics, Inc. - Nalu Medical, Inc. - electroCore, Inc. - BioWave Corporation - CEFALY Technology - CEFALY US, INC - ShiraTronics, Inc. - CorTec - Presidio Medical, Inc. - Neuspera Medical Inc. - Polar Medical Ltd. - Polar Medical Supply LLC #neuromodulation #neuromodulationmarket

Medtronic, Boston Scientific and other medtech leaders are competing to commercialize catheter technology with roots in Minnesota that’s making atrial fibrillation treatment safer.

As someone with a parent affected by Atrial Fibrillation (AFib), this topic hits close to home for me. AFib affects about 10.5 million Americans, causing irregular heart rhythms that can lead to serious complications like stroke and heart failure. To improve treatment, companies like Boston Scientific, Johnson & Johnson MedTech, and Medtronic are investing in Pulsed Field Ablation (PFA), a new technology that uses electrical pulses instead of thermal energy to create lesions in the heart. This approach is designed to be safer, more precise, and reduce complications. (read more in the Mass Device article below) My passion for MedTech comes from the impact it’s had on my own life, and I’ve dedicated my career by making a difference through technology moving forward. I love to see companies continue to innovate to drive patient outcomes. Keep innovating! #MedTech #Innovation #JnJ #Medtronic #BostonScientific #Stryker #Hologic #ZimmerBiomet 📰: MassDevice https://lnkd.in/gDKXfDuq

👏 The new financing allows Kardium Inc. to complete the PULSAR clinical study of its Globe Pulsed Field Ablation system and use the results to obtain regulatory approvals. 🗣 Kevin Chaplin, CEO of Kardium, commented: “[The investors'] enthusiasm and support reflect the incredible success we have achieved with the Globe system and the tremendous potential we have to dramatically improve the treatment of atrial fibrillation for millions of patients worldwide.” 🔗 Read more: https://lnkd.in/day6yhVk 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dh3kMf-a #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions

A First Step into bringing Novel US FDA Breakthrough technology to the US , A Giant Leap of Hope & Promise for US based Patients suffering from complex Coronary occlusive vascular disease . Concept Medical is proud to announce commencement of its Pivotal US FDA Investigational Devise Exemption Study for the treatment of Instent Restenosis with Magic Touch SCB - The World's 1st CE commercialized Novel Sirolimus Drug Coated Balloon , offering a safer and effective alternative for treatment of complex coronary disease such as InStent Restenosis . We are thankful to Dr Ajay Kirtane , Dr Azeem Latib , the principal investigators of the study and all the US study investigators supporting the enrollment and treatment in this pivotal multi- centered Randomised clinical trial. With Over 23K patients touched with Its clinical trial program with results that are altering standards of care and shaping the future of percutaneous treatment of occlusive vascular disease with over 180 K patients treated in real world setting with its solutions accross vascular disease , this milestone is indeed an important step to extend these proven technlogies to ailing patients in the US # Worlds 1st CE commercialized Sirolimus DCB #US FDA Breakthrough Devices # Largest and Longest Studied Clinical trial program touching over 23 K patients # over 180 K patients treated - Confidence Inspired by Real World Use.

🌟 Exciting Announcement: Liquid Lipid Disposable Cannulas Now Distributed by LIPOELASTIC United Kingdom 🌟 I’m proud to announce that the Liquid Lipid portfolio, featuring advanced fat harvesting and grafting instruments, is now officially available through LIPOELASTIC! The Liquid Lipid range was developed to address real challenges in the operating room, providing reliable and efficient tools for fat grafting and harvesting. With a focus on comfort, durability, and precision, these instruments are designed to help clinicians make the most of the incredible potential of fat in medicine—whether it’s for stem cell technology, wound healing, breast reconstruction, or aesthetics. Featuring solid hubs, friction bonding, and reusable-grade stainless steel, this range offers dependable performance in every procedure. We’re excited to bring these high-quality products to practitioners, making fat grafting more accessible across the UK. 🔗 https://lnkd.in/e9QxFe7S Looking forward to connecting with those interested in learning more! #NewDistribution #Lipoelastic #Innovation #LiquidLipid #FatGrafting #ProductLaunch #Healthcare #MedicalInnovation